AVTR Earnings Date: Feb 10, 2027 (Estimated) — Avantor, Inc.
NYSE · Healthcare · Medical Instruments & Supplies
Updated
When is AVTR's next earnings date?
Avantor, Inc. (AVTR) is expected to report Q4 2026 earnings on Wednesday, February 10, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.23 on revenue of $1.68B.
How did AVTR do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), Avantor, Inc. posted EPS of $0.22 versus the $0.21 estimate, a beat of 5.3%. Revenue was $1.70B against a $1.64B estimate. The stock's 1-day post-earnings move was -2.6%.
How much does AVTR stock move after earnings?
AVTR beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.4% (up or down) in the day after earnings.
About Avantor, Inc.
Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone materials, tailored excipients, single-use assemblies, process chromatography resins and columns, analytical sample preparation kits, educational and microbiology products, clinical trial kits, peristaltic pumps, and various fluid handling tips. Beyond consumables, Avantor also supplies advanced equipment and instrumentation. This range includes filtration and virus inactivation systems, incubators, analytical devices, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. Complementing its product offerings, Avantor delivers a suite of crucial services. These encompass on-site laboratory and production support, clinical services, equipment maintenance, comprehensive procurement and sourcing solutions, and specialized biopharmaceutical material scale-up and development expertise.
🤖 AI Earnings Analysis
Avantor’s Q3 was strong: sales rose 4.6% to $1.70B, beating estimates, and management raised full-year organic growth, adjusted EPS and free-cash-flow guidance. Adjusted EPS of $0.22 modestly beat.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | 0.21 | 0.22 | +5.26% | $1.70B | ✅ Beat | -2.57% | — | — |
| 2026-07-29 | Q2 2026 | 0.19 | 0.21 | +10.53% | $1.69B | ✅ Beat | +15.78% | +10.14% | +16.75% |
| 2026-04-29 | Q1 2026 | 0.16 | 0.17 | +6.25% | $1.58B | ✅ Beat | -0.13% | +2.42% | +16.41% |
| 2026-02-11 | Q4 2025 | 0.21 | 0.22 | +4.76% | $1.66B | ✅ Beat | -13.62% | -16.94% | -29.21% |
| 2025-10-29 | Q3 2025 | 0.23 | 0.22 | -4.35% | $1.62B | ❌ Miss | -23.21% | -23.21% | -22.15% |
| 2025-08-01 | Q2 2025 | 0.25 | 0.24 | -4.00% | $1.68B | ❌ Miss | -15.48% | -15.33% | +0.22% |
| 2025-04-25 | Q1 2025 | 0.23 | 0.23 | — | $1.58B | ➖ Inline | -16.58% | -16.39% | -18.13% |
| 2025-02-07 | Q4 2024 | 0.26 | 0.27 | +3.85% | $1.69B | ✅ Beat | -11.71% | -16.59% | -20.37% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $1.70B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Proprietary Materials And Consumables | 53.5% | $907.9M | +6.1% | $829.7M | $893.8M | $855.6M | $869.8M |
| Third Party Materials And Consumables | 46.5% | $790.4M | +2.9% | $751.7M | $789.6M | $768.2M | $793.8M |
By region
Q4 FY23 · $1.60B total
| Segment | Share | Revenue | YoY | Q2 FY22 | Q3 FY22 | Q4 FY22 | Q1 FY23 |
|---|---|---|---|---|---|---|---|
| Americas | 62.2% | $994.8M | -5.1% | $1.16B | $1.12B | $1.05B | $1.03B |
| Europe | 37.8% | $603.5M | -2.2% | $623.8M | $595.1M | $617.2M | $630.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.